메뉴 건너뛰기




Volumn 8, Issue 12, 2013, Pages

Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 Clade C

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; POLYPEPTIDE; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

EID: 84891605288     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082380     Document Type: Article
Times cited : (23)

References (67)
  • 1
    • 34249068954 scopus 로고    scopus 로고
    • An HIV-1 vaccine-evolving concepts
    • doi:10.1056/NEJMra066267. PubMed: 17507706
    • Johnston MI, Fauci AS (2007) An HIV-1 vaccine-evolving concepts. N Engl J Med 356: 2073-2081. doi:10.1056/NEJMra066267. PubMed: 17507706.
    • (2007) N Engl J Med , vol.356 , pp. 2073-2081
    • Johnston, M.I.1    Fauci, A.S.2
  • 2
    • 33646172660 scopus 로고    scopus 로고
    • HIV vaccines
    • doi:10.1146/annurev.immunol.24.021605.090605. PubMed: 16551249
    • McMichael AJ (2006) HIV vaccines. Annu Rev Immunol 24: 227-255. doi:10.1146/annurev.immunol.24.021605.090605. PubMed: 16551249.
    • (2006) Annu Rev Immunol , vol.24 , pp. 227-255
    • McMichael, A.J.1
  • 3
    • 56649105122 scopus 로고    scopus 로고
    • Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial
    • doi:10.1016/S0140-6736(08)61591-3. PubMed: 19012954
    • Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893. doi:10.1016/S0140-6736(08)61591-3. PubMed: 19012954.
    • (2008) Lancet , vol.372 , pp. 1881-1893
    • Buchbinder, S.P.1    Mehrotra, D.V.2    Duerr, A.3    Fitzgerald, D.W.4    Mogg, R.5
  • 4
    • 13944254982 scopus 로고    scopus 로고
    • Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection
    • doi:10.1086/428404. PubMed: 15688278
    • Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH et al. (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665. doi:10.1086/428404. PubMed: 15688278.
    • (2005) J Infect Dis , vol.191 , pp. 654-665
    • Flynn, N.M.1    Forthal, D.N.2    Harro, C.D.3    Judson, F.N.4    Mayer, K.H.5
  • 5
    • 73349094086 scopus 로고    scopus 로고
    • Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    • doi:10.1056/NEJMoa0908492. PubMed: 19843557
    • Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220. doi:10.1056/NEJMoa0908492. PubMed: 19843557.
    • (2009) N Engl J Med , vol.361 , pp. 2209-2220
    • Rerks-Ngarm, S.1    Pitisuttithum, P.2    Nitayaphan, S.3    Kaewkungwal, J.4    Chiu, J.5
  • 7
    • 84891585599 scopus 로고    scopus 로고
    • National Institute of Allergy and Infectious Diseases National Institutes of Health Updated April 25th
    • National Institute of Allergy and Infectious Diseases National Institutes of Health (2013) QUESTIONS AND ANSWERS : The HVTN 505 HIV Vaccine Regimen Study. Updated April 25th.
    • (2013) QUESTIONS and ANSWERS: The HVTN 505 HIV Vaccine Regimen Study
  • 8
    • 84875579579 scopus 로고    scopus 로고
    • Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E
    • doi:10.1093/infdis/jis478. PubMed: 22837492
    • Rerks-Ngarm S, Paris RM, Chunsutthiwat S, Premsri N, Namwat C et al. (2013) Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis 207: 1195-1205. doi:10.1093/infdis/ jis478. PubMed: 22837492.
    • (2013) J Infect Dis , vol.207 , pp. 1195-1205
    • Rerks-Ngarm, S.1    Paris, R.M.2    Chunsutthiwat, S.3    Premsri, N.4    Namwat, C.5
  • 9
    • 73349084980 scopus 로고    scopus 로고
    • HIV vaccine trial results - An opening for further research
    • doi:10.1056/NEJMe0909972. PubMed: 19843556
    • Dolin R (2009) HIV vaccine trial results - an opening for further research. N Engl J Med 361: 2279-2280. doi:10.1056/NEJMe0909972. PubMed: 19843556.
    • (2009) N Engl J Med , vol.361 , pp. 2279-2280
    • Dolin, R.1
  • 10
    • 84861173075 scopus 로고    scopus 로고
    • The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope
    • doi:10.4049/jimmunol.1102756. PubMed: 22529301
    • de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S et al. (2012) The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 188: 5166-5176. doi:10.4049/jimmunol.1102756. PubMed: 22529301.
    • (2012) J Immunol , vol.188 , pp. 5166-5176
    • De Souza, M.S.1    Ratto-Kim, S.2    Chuenarom, W.3    Schuetz, A.4    Chantakulkij, S.5
  • 11
    • 84859393693 scopus 로고    scopus 로고
    • Immune-correlates analysis of an HIV-1 vaccine efficacy trial
    • doi:10.1056/NEJMoa1113425. PubMed: 22475592
    • Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286. doi:10.1056/NEJMoa1113425. PubMed: 22475592.
    • (2012) N Engl J Med , vol.366 , pp. 1275-1286
    • Haynes, B.F.1    Gilbert, P.B.2    McElrath, M.J.3    Zolla-Pazner, S.4    Tomaras, G.D.5
  • 12
    • 77954357410 scopus 로고    scopus 로고
    • Correlates of protection induced by vaccination
    • doi:10.1128/CVI.00131-10. PubMed: 20463105
    • Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17: 1055-1065. doi:10.1128/CVI.00131-10. PubMed: 20463105.
    • (2010) Clin Vaccine Immunol , vol.17 , pp. 1055-1065
    • Plotkin, S.A.1
  • 13
    • 2942534479 scopus 로고    scopus 로고
    • Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies
    • doi:10.1086/420833. PubMed: 15181562
    • Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T et al. (2004) Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 189: 2167-2173. doi:10.1086/420833. PubMed: 15181562.
    • (2004) J Infect Dis , vol.189 , pp. 2167-2173
    • Ferrantelli, F.1    Rasmussen, R.A.2    Buckley, K.A.3    Li, P.L.4    Wang, T.5
  • 14
    • 67249131966 scopus 로고    scopus 로고
    • Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers
    • PubMed: 19436712
    • Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G et al. (2009) Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 5: e1000433. PubMed: 19436712.
    • (2009) PLoS Pathog , vol.5
    • Hessell, A.J.1    Rakasz, E.G.2    Poignard, P.3    Hangartner, L.4    Landucci, G.5
  • 15
    • 0032947286 scopus 로고    scopus 로고
    • Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
    • PubMed: 10196297
    • Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC et al. (1999) Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73: 4009-4018. PubMed: 10196297.
    • (1999) J Virol , vol.73 , pp. 4009-4018
    • Mascola, J.R.1    Lewis, M.G.2    Stiegler, G.3    Harris, D.4    VanCott, T.C.5
  • 16
    • 0034864776 scopus 로고    scopus 로고
    • Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro
    • doi: 10.1128/JVI.75.17.8340-8347.2001. PubMed: 11483779
    • Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J et al. (2001) Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 75: 8340-8347. doi: 10.1128/JVI.75.17.8340- 8347.2001. PubMed: 11483779.
    • (2001) J Virol , vol.75 , pp. 8340-8347
    • Parren, P.W.1    Marx, P.A.2    Hessell, A.J.3    Luckay, A.4    Harouse, J.5
  • 17
    • 84855466746 scopus 로고    scopus 로고
    • Antibody-based protection against HIV infection by vectored immunoprophylaxis
    • PubMed: 22139420
    • Balazs AB, Chen J, Hong CM, Rao DS, Yang L et al. (2012) Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481: 81-84. PubMed: 22139420.
    • (2012) Nature , vol.481 , pp. 81-84
    • Balazs, A.B.1    Chen, J.2    Hong, C.M.3    Rao, D.S.4    Yang, L.5
  • 18
    • 84866250119 scopus 로고    scopus 로고
    • Gene therapy as a vaccine for HIV-1
    • doi:10.1517/14712598.2012.707177. PubMed: 22803517
    • Berkhout B, Sanders RW (2012) Gene therapy as a vaccine for HIV-1. Expert Opin Biol Ther 12: 1315-1321. doi:10.1517/14712598.2012.707177. PubMed: 22803517.
    • (2012) Expert Opin Biol Ther , vol.12 , pp. 1315-1321
    • Berkhout, B.1    Sanders, R.W.2
  • 19
    • 77954722964 scopus 로고    scopus 로고
    • Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine
    • doi:10.1086/654816. PubMed: 20608874
    • Gilbert P, Wang M, Wrin T, Petropoulos C, Gurwith M et al. (2010) Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 202: 595-605. doi:10.1086/654816. PubMed: 20608874.
    • (2010) J Infect Dis , vol.202 , pp. 595-605
    • Gilbert, P.1    Wang, M.2    Wrin, T.3    Petropoulos, C.4    Gurwith, M.5
  • 20
    • 24644479045 scopus 로고    scopus 로고
    • HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine
    • doi:10.1086/432734. PubMed: 16107949
    • Gilbert PB, Ackers ML, Berman PW, Francis DP, Popovic V et al. (2005) HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 192: 974-983. doi:10.1086/432734. PubMed: 16107949.
    • (2005) J Infect Dis , vol.192 , pp. 974-983
    • Gilbert, P.B.1    Ackers, M.L.2    Berman, P.W.3    Francis, D.P.4    Popovic, V.5
  • 21
    • 13944250922 scopus 로고    scopus 로고
    • Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial
    • doi:10.1086/428405. PubMed: 15688279
    • Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP et al. (2005) Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191: 666-677. doi:10.1086/428405. PubMed: 15688279.
    • (2005) J Infect Dis , vol.191 , pp. 666-677
    • Gilbert, P.B.1    Peterson, M.L.2    Follmann, D.3    Hudgens, M.G.4    Francis, D.P.5
  • 22
    • 33845433434 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    • doi:10.1086/508748. PubMed: 17109337
    • Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671. doi:10.1086/508748. PubMed: 17109337.
    • (2006) J Infect Dis , vol.194 , pp. 1661-1671
    • Pitisuttithum, P.1    Gilbert, P.2    Gurwith, M.3    Heyward, W.4    Martin, M.5
  • 23
    • 84862904805 scopus 로고    scopus 로고
    • Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)
    • doi:10.1093/infdis/jis342. PubMed: 22561365
    • Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J et al. (2012) Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 206: 258-266. doi:10.1093/infdis/jis342. PubMed: 22561365.
    • (2012) J Infect Dis , vol.206 , pp. 258-266
    • Duerr, A.1    Huang, Y.2    Buchbinder, S.3    Coombs, R.W.4    Sanchez, J.5
  • 24
    • 84875771414 scopus 로고    scopus 로고
    • Antigenicity and Immunogenicity of Transmitted/Founder, Consensus and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1
    • Liao HX, Tsao CY, Alam SM, Muldoon M, Vandergrift N et al. (2013) Antigenicity and Immunogenicity of Transmitted/Founder, Consensus and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1. J Virol.
    • (2013) J Virol
    • Liao, H.X.1    Tsao, C.Y.2    Alam, S.M.3    Muldoon, M.4    Vandergrift, N.5
  • 25
    • 84874277923 scopus 로고    scopus 로고
    • Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: A randomised, double-blind, placebo-controlled, phase 1 study
    • doi:10.1016/S1473-3099(12)70345-6. PubMed: 23369412
    • Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J et al. (2013) Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 13: 238-250. doi:10.1016/S1473-3099(12)70345-6. PubMed: 23369412.
    • (2013) Lancet Infect Dis , vol.13 , pp. 238-250
    • Gurwith, M.1    Lock, M.2    Taylor, E.M.3    Ishioka, G.4    Alexander, J.5
  • 26
    • 84878528694 scopus 로고    scopus 로고
    • Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design
    • doi:10.1128/JVI.03577-12. PubMed: 23616655
    • Ping LH, Joseph SB, Anderson JA, Abrahams MR, Salazar-Gonzalez JF et al. (2013) Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design. J Virol 87: 7218-7233. doi:10.1128/JVI.03577-12. PubMed: 23616655.
    • (2013) J Virol , vol.87 , pp. 7218-7233
    • Ping, L.H.1    Joseph, S.B.2    Anderson, J.A.3    Abrahams, M.R.4    Salazar-Gonzalez, J.F.5
  • 27
    • 77649145875 scopus 로고    scopus 로고
    • Characterization of transgene expression in adenoviral vector-based HIV-1 vaccine candidates
    • doi:10.1186/1743-422X-7-39. PubMed: 20163742
    • Takahashi MN, Rolling JA, Owen KE (2010) Characterization of transgene expression in adenoviral vector-based HIV-1 vaccine candidates. Virol J 7: 39. doi:10.1186/1743-422X-7-39. PubMed: 20163742.
    • (2010) Virol J , vol.7 , pp. 39
    • Takahashi, M.N.1    Rolling, J.A.2    Owen, K.E.3
  • 29
    • 84857177060 scopus 로고    scopus 로고
    • Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin
    • doi:10.1371/journal.pone.0031177. PubMed: 22363572
    • Alexander J, Ward S, Mendy J, Manayani DJ, Farness P et al. (2012) Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLOS ONE 7: e31177. doi:10.1371/journal.pone.0031177. PubMed: 22363572.
    • (2012) PLOS ONE , vol.7
    • Alexander, J.1    Ward, S.2    Mendy, J.3    Manayani, D.J.4    Farness, P.5
  • 30
    • 16944365650 scopus 로고    scopus 로고
    • Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles
    • doi:10.1089/hum.1997.8.4-453. PubMed: 9054520
    • Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT et al. (1997) Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 8: 453-465. doi:10.1089/hum.1997.8.4-453. PubMed: 9054520.
    • (1997) Hum Gene Ther , vol.8 , pp. 453-465
    • Shabram, P.W.1    Giroux, D.D.2    Goudreau, A.M.3    Gregory, R.J.4    Horn, M.T.5
  • 31
    • 70350134276 scopus 로고    scopus 로고
    • Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins
    • doi:10.1016/j.virol.2009.07.041. PubMed: 19744690
    • Gao F, Scearce RM, Alam SM, Hora B, Xia S et al. (2009) Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. Virology 394: 91-98. doi:10.1016/j.virol.2009.07.041. PubMed: 19744690.
    • (2009) Virology , vol.394 , pp. 91-98
    • Gao, F.1    Scearce, R.M.2    Alam, S.M.3    Hora, B.4    Xia, S.5
  • 32
    • 0032210842 scopus 로고    scopus 로고
    • Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120
    • doi:10.1016/S0264-410X(98)00182-0. PubMed: 9795384
    • Pinter A, Honnen WJ, Kayman SC, Trochev O, Wu Z (1998) Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 16: 1803-1811. doi:10.1016/S0264-410X(98)00182-0. PubMed: 9795384.
    • (1998) Vaccine , vol.16 , pp. 1803-1811
    • Pinter, A.1    Honnen, W.J.2    Kayman, S.C.3    Trochev, O.4    Wu, Z.5
  • 33
    • 84873051328 scopus 로고    scopus 로고
    • Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion
    • doi:10.1128/JVI.00718-12. PubMed: 23175357
    • Alam SM, Liao HX, Tomaras GD, Bonsignori M, Tsao CY et al. (2013) Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol 87: 1554-1568. doi:10.1128/JVI.00718-12. PubMed: 23175357.
    • (2013) J Virol , vol.87 , pp. 1554-1568
    • Alam, S.M.1    Liao, H.X.2    Tomaras, G.D.3    Bonsignori, M.4    Tsao, C.Y.5
  • 34
    • 84891588664 scopus 로고    scopus 로고
    • Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes with V1/V2
    • doi:10.1186/1742-4690-9-S2-O31
    • Liao L, Bonsignori M, Hwang KK, Moody MA, Park R et al. (2012) Design of an HIV Env antigen that binds with high affinity to antibodies against linear, conformational and broadly neutralizing epitopes with V1/V2. Retrovirology 9(Suppl 2): O31. doi:10.1186/1742-4690-9-S2-O31.
    • (2012) Retrovirology , vol.9 , Issue.SUPPL. 2
    • Liao, L.1    Bonsignori, M.2    Hwang, K.K.3    Moody, M.A.4    Park, R.5
  • 35
    • 84863932778 scopus 로고    scopus 로고
    • Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
    • doi:10.1093/infdis/jis367. PubMed: 22634875
    • Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P et al. (2012) Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis 206: 431-441. doi:10.1093/infdis/jis367. PubMed: 22634875.
    • (2012) J Infect Dis , vol.206 , pp. 431-441
    • Montefiori, D.C.1    Karnasuta, C.2    Huang, Y.3    Ahmed, H.4    Gilbert, P.5
  • 36
    • 73949127978 scopus 로고    scopus 로고
    • Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies
    • doi:10.1128/JVI.02108-09. PubMed: 19939925
    • Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C et al. (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84: 1439-1452. doi:10.1128/JVI.02108-09. PubMed: 19939925.
    • (2010) J Virol , vol.84 , pp. 1439-1452
    • Seaman, M.S.1    Janes, H.2    Hawkins, N.3    Grandpre, L.E.4    Devoy, C.5
  • 37
    • 83455254775 scopus 로고    scopus 로고
    • Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
    • doi:10.1038/nature10696. PubMed: 22113616
    • McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336-343. doi:10.1038/nature10696. PubMed: 22113616.
    • (2011) Nature , vol.480 , pp. 336-343
    • McLellan, J.S.1    Pancera, M.2    Carrico, C.3    Gorman, J.4    Julien, J.P.5
  • 38
    • 80051737642 scopus 로고    scopus 로고
    • HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation
    • doi:10.1016/j.jmb.2011.04.042. PubMed: 21762802
    • Checkley MA, Luttge BG, Freed EO (2011) HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 410: 582-608. doi:10.1016/j.jmb.2011.04.042. PubMed: 21762802.
    • (2011) J Mol Biol , vol.410 , pp. 582-608
    • Checkley, M.A.1    Luttge, B.G.2    Freed, E.O.3
  • 39
    • 0022458750 scopus 로고
    • Infectious mutants of HTLV-III with changes in the 3′ region and markedly reduced cytopathic effects
    • doi: 10.1126/science.3014663. PubMed: 3014663
    • Fisher AG, Ratner L, Mitsuya H, Marselle LM, Harper ME et al. (1986) Infectious mutants of HTLV-III with changes in the 3′ region and markedly reduced cytopathic effects. Science 233: 655-659. doi: 10.1126/science.3014663. PubMed: 3014663.
    • (1986) Science , vol.233 , pp. 655-659
    • Fisher, A.G.1    Ratner, L.2    Mitsuya, H.3    Marselle, L.M.4    Harper, M.E.5
  • 40
    • 0024375181 scopus 로고
    • Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity
    • doi:10.1089/aid.1989.5.441. PubMed: 2788444
    • Lee SJ, Hu W, Fisher AG, Looney DJ, Kao VF et al. (1989) Role of the carboxy-terminal portion of the HIV-1 transmembrane protein in viral transmission and cytopathogenicity. AIDS Res Hum Retroviruses 5: 441-449. doi:10.1089/aid.1989.5.441. PubMed: 2788444.
    • (1989) AIDS Res Hum Retroviruses , vol.5 , pp. 441-449
    • Lee, S.J.1    Hu, W.2    Fisher, A.G.3    Looney, D.J.4    Kao, V.F.5
  • 41
    • 84871950126 scopus 로고    scopus 로고
    • The tale of the long tail: The cytoplasmic domain of HIV-1 gp41
    • doi:10.1128/JVI.02053-12. PubMed: 23077317
    • Postler TS, Desrosiers RC (2013) The tale of the long tail: the cytoplasmic domain of HIV-1 gp41. J Virol 87: 2-15. doi:10.1128/JVI.02053-12. PubMed: 23077317.
    • (2013) J Virol , vol.87 , pp. 2-15
    • Postler, T.S.1    Desrosiers, R.C.2
  • 42
    • 67650444362 scopus 로고    scopus 로고
    • Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity
    • doi:10.1128/JVI.00374-09. PubMed: 19420074
    • Wang L, Cheng C, Ko SY, Kong WP, Kanekiyo M et al. (2009) Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity. J Virol 83: 7166-7175. doi:10.1128/JVI.00374-09. PubMed: 19420074.
    • (2009) J Virol , vol.83 , pp. 7166-7175
    • Wang, L.1    Cheng, C.2    Ko, S.Y.3    Kong, W.P.4    Kanekiyo, M.5
  • 43
    • 84868589536 scopus 로고    scopus 로고
    • The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120
    • doi:10.1089/aid.2012.0103. PubMed: 23035746
    • Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S et al. (2012) The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 28: 1444-1457. doi:10.1089/aid.2012.0103. PubMed: 23035746.
    • (2012) AIDS Res Hum Retroviruses , vol.28 , pp. 1444-1457
    • Karasavvas, N.1    Billings, E.2    Rao, M.3    Williams, C.4    Zolla-Pazner, S.5
  • 44
    • 84867653590 scopus 로고    scopus 로고
    • Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2
    • doi:10.1038/nature11519. PubMed: 22960785
    • Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E et al. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490: 417-420. doi:10.1038/nature11519. PubMed: 22960785.
    • (2012) Nature , vol.490 , pp. 417-420
    • Rolland, M.1    Edlefsen, P.T.2    Larsen, B.B.3    Tovanabutra, S.4    Sanders-Buell, E.5
  • 45
    • 2342644898 scopus 로고    scopus 로고
    • The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection
    • doi:10.1128/JVI.78.10.5205-5215.2004. PubMed: 15113902
    • Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S et al. (2004) The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 78: 5205-5215. doi:10.1128/JVI.78.10.5205-5215. 2004. PubMed: 15113902.
    • (2004) J Virol , vol.78 , pp. 5205-5215
    • Pinter, A.1    Honnen, W.J.2    He, Y.3    Gorny, M.K.4    Zolla-Pazner, S.5
  • 46
    • 33748925430 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity
    • doi:10.1128/JVI.00141-06. PubMed: 16973562
    • Sagar M, Wu X, Lee S, Overbaugh J (2006) Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J Virol 80: 9586-9598. doi:10.1128/JVI.00141-06. PubMed: 16973562.
    • (2006) J Virol , vol.80 , pp. 9586-9598
    • Sagar, M.1    Wu, X.2    Lee, S.3    Overbaugh, J.4
  • 47
    • 73949112038 scopus 로고    scopus 로고
    • The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1
    • doi:10.1073/pnas.0911796106. PubMed: 19933330
    • Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R et al. (2009) The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A 106: 20877-20882. doi:10.1073/pnas.0911796106. PubMed: 19933330.
    • (2009) Proc Natl Acad Sci U S A , vol.106 , pp. 20877-20882
    • Cicala, C.1    Martinelli, E.2    McNally, J.P.3    Goode, D.J.4    Gopaul, R.5
  • 48
    • 79952232940 scopus 로고    scopus 로고
    • The genotype of early-transmitting HIV gp120s promotes alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +/CD4+ T cells as key targets in mucosal transmission
    • Nawaz F, Cicala C, Van Ryk D, Block KE, Jelicic K et al. (2011) The genotype of early-transmitting HIV gp120s promotes alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +/CD4+ T cells as key targets in mucosal transmission. PLOS Pathog 7: e1001301.
    • (2011) PLOS Pathog , vol.7
    • Nawaz, F.1    Cicala, C.2    Van Ryk, D.3    Block, K.E.4    Jelicic, K.5
  • 49
    • 84862828547 scopus 로고    scopus 로고
    • Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals
    • doi:10.1016/j.virol.2012.02.003. PubMed: 22402248
    • Gorny MK, Pan R, Williams C, Wang XH, Volsky B et al. (2012) Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology 427: 198-207. doi:10.1016/j.virol.2012.02. 003. PubMed: 22402248.
    • (2012) Virology , vol.427 , pp. 198-207
    • Gorny, M.K.1    Pan, R.2    Williams, C.3    Wang, X.H.4    Volsky, B.5
  • 50
    • 80053132436 scopus 로고    scopus 로고
    • Broad neutralization coverage of HIV by multiple highly potent antibodies
    • doi:10.1038/nature10373. PubMed: 21849977
    • Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470. doi:10.1038/nature10373. PubMed: 21849977.
    • (2011) Nature , vol.477 , pp. 466-470
    • Walker, L.M.1    Huber, M.2    Doores, K.J.3    Falkowska, E.4    Pejchal, R.5
  • 51
    • 77951882041 scopus 로고    scopus 로고
    • Toward an antibody-based HIV-1 vaccine
    • doi:10.1146/annurev.med.60.042507.164323. PubMed: 19824826
    • Hoxie JA (2010) Toward an antibody-based HIV-1 vaccine. Annu Rev Med 61: 135-152. doi:10.1146/annurev.med.60.042507.164323. PubMed: 19824826.
    • (2010) Annu Rev Med , vol.61 , pp. 135-152
    • Hoxie, J.A.1
  • 52
    • 77952311370 scopus 로고    scopus 로고
    • The role of antibodies in HIV vaccines
    • doi:10.1146/annurev-immunol-030409-101256. PubMed: 20192810
    • Mascola JR, Montefiori DC (2010) The role of antibodies in HIV vaccines. Annu Rev Immunol 28: 413-444. doi:10.1146/annurev-immunol-030409-101256. PubMed: 20192810.
    • (2010) Annu Rev Immunol , vol.28 , pp. 413-444
    • Mascola, J.R.1    Montefiori, D.C.2
  • 53
    • 84857306337 scopus 로고    scopus 로고
    • Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site
    • doi:10.1074/jbc.M111.317776. PubMed: 22167180
    • Feng Y, McKee K, Tran K, O'Dell S, Schmidt SD et al. (2012) Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. J Biol Chem 287: 5673-5686. doi:10.1074/jbc.M111.317776. PubMed: 22167180.
    • (2012) J Biol Chem , vol.287 , pp. 5673-5686
    • Feng, Y.1    McKee, K.2    Tran, K.3    O'Dell, S.4    Schmidt, S.D.5
  • 54
    • 80052938385 scopus 로고    scopus 로고
    • Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
    • doi:10.1128/JVI.05045-11. PubMed: 21795340
    • Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L et al. (2011) Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 85: 9998-10009. doi:10.1128/JVI.05045-11. PubMed: 21795340.
    • (2011) J Virol , vol.85 , pp. 9998-10009
    • Bonsignori, M.1    Hwang, K.K.2    Chen, X.3    Tsao, C.Y.4    Morris, L.5
  • 55
    • 77649318846 scopus 로고    scopus 로고
    • Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals
    • doi:10.1371/journal.pone.0008805. PubMed: 20098712
    • Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F et al. (2010) Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLOS ONE 5: e8805. doi:10.1371/journal.pone.0008805. PubMed: 20098712.
    • (2010) PLOS ONE , vol.5
    • Corti, D.1    Langedijk, J.P.2    Hinz, A.3    Seaman, M.S.4    Vanzetta, F.5
  • 56
    • 33646146379 scopus 로고    scopus 로고
    • GP120: Target for neutralizing HIV-1 antibodies
    • doi:10.1146/annurev.immunol.24.021605.090557. PubMed: 16551265
    • Pantophlet R, Burton DR (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24: 739-769. doi:10.1146/annurev.immunol.24.021605. 090557. PubMed: 16551265.
    • (2006) Annu Rev Immunol , vol.24 , pp. 739-769
    • Pantophlet, R.1    Burton, D.R.2
  • 57
    • 80052925616 scopus 로고    scopus 로고
    • Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
    • doi:10.1126/science.1207227. PubMed: 21764753
    • Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F et al. (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333: 1633-1637. doi:10.1126/science.1207227. PubMed: 21764753.
    • (2011) Science , vol.333 , pp. 1633-1637
    • Scheid, J.F.1    Mouquet, H.2    Ueberheide, B.3    Diskin, R.4    Klein, F.5
  • 58
    • 0032546844 scopus 로고    scopus 로고
    • The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
    • doi:10.1126/science.280.5371.1884. PubMed: 9632381
    • Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888. doi:10.1126/science.280.5371. 1884. PubMed: 9632381.
    • (1998) Science , vol.280 , pp. 1884-1888
    • Wyatt, R.1    Sodroski, J.2
  • 59
    • 70449701456 scopus 로고    scopus 로고
    • Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens
    • doi:10.1016/j.bbrc.2009.09.029. PubMed: 19748484
    • Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P et al. (2009) Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 390: 404-409. doi:10.1016/j.bbrc.2009.09.029. PubMed: 19748484.
    • (2009) Biochem Biophys Res Commun , vol.390 , pp. 404-409
    • Xiao, X.1    Chen, W.2    Feng, Y.3    Zhu, Z.4    Prabakaran, P.5
  • 60
    • 84867902637 scopus 로고    scopus 로고
    • HIV-1 antibodies from infection and vaccination: Insights for guiding vaccine design
    • doi:10.1016/j.tim.2012.08.011. PubMed: 22981828
    • Bonsignori M, Alam SM, Liao HX, Verkoczy L, Tomaras GD et al. (2012) HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol 20: 532-539. doi:10.1016/j.tim.2012.08.011. PubMed: 22981828.
    • (2012) Trends Microbiol , vol.20 , pp. 532-539
    • Bonsignori, M.1    Alam, S.M.2    Liao, H.X.3    Verkoczy, L.4    Tomaras, G.D.5
  • 61
    • 84860759632 scopus 로고    scopus 로고
    • B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study
    • doi:10.1038/nbt.2197. PubMed: 22565972
    • Haynes BF, Kelsoe G, Harrison SC, Kepler TB (2012) B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol 30: 423-433. doi:10.1038/nbt.2197. PubMed: 22565972.
    • (2012) Nat Biotechnol , vol.30 , pp. 423-433
    • Haynes, B.F.1    Kelsoe, G.2    Harrison, S.C.3    Kepler, T.B.4
  • 62
    • 82955201800 scopus 로고    scopus 로고
    • Prospects for an HIV vaccine: Leading B cells down the right path
    • doi:10.1038/nsmb.2194. PubMed: 22139037
    • Moir S, Malaspina A, Fauci AS (2011) Prospects for an HIV vaccine: leading B cells down the right path. Nat Struct Mol Biol 18: 1317-1321. doi:10.1038/nsmb.2194. PubMed: 22139037.
    • (2011) Nat Struct Mol Biol , vol.18 , pp. 1317-1321
    • Moir, S.1    Malaspina, A.2    Fauci, A.S.3
  • 63
    • 33947590277 scopus 로고    scopus 로고
    • A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120
    • doi:10.1016/j.virol.2006.10.032. PubMed: 17126869
    • Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP et al. (2007) A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360: 329-340. doi:10.1016/j.virol.2006.10.032. PubMed: 17126869.
    • (2007) Virology , vol.360 , pp. 329-340
    • Beddows, S.1    Franti, M.2    Dey, A.K.3    Kirschner, M.4    Iyer, S.P.5
  • 64
    • 79551556431 scopus 로고    scopus 로고
    • Heterologous epitope-scaffold prime:Boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant
    • doi:10.1371/journal.pone.0016074. PubMed: 21297864
    • Guenaga J, Dosenovic P, Ofek G, Baker D, Schief WR et al. (2011) Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLOS ONE 6: e16074. doi:10.1371/journal.pone.0016074. PubMed: 21297864.
    • (2011) PLOS ONE , vol.6
    • Guenaga, J.1    Dosenovic, P.2    Ofek, G.3    Baker, D.4    Schief, W.R.5
  • 65
    • 84861324362 scopus 로고    scopus 로고
    • HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes
    • doi:10.1128/JVI.06938-11. PubMed: 22301141
    • Tong T, Crooks ET, Osawa K, Binley JM (2012) HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. J Virol 86: 3574-3587. doi:10.1128/JVI.06938-11. PubMed: 22301141.
    • (2012) J Virol , vol.86 , pp. 3574-3587
    • Tong, T.1    Crooks, E.T.2    Osawa, K.3    Binley, J.M.4
  • 66
    • 80053952246 scopus 로고    scopus 로고
    • Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120
    • doi:10.1128/JVI.05086-11
    • Zolla-Pazner S, Kong XP, Jiang X, Cardozo T, Nadas A et al. (2011) Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120. DNA - J Virol 85: 9887-9898. doi:10.1128/JVI.05086-11.
    • (2011) DNA - J Virol , vol.85 , pp. 9887-9898
    • Zolla-Pazner, S.1    Kong, X.P.2    Jiang, X.3    Cardozo, T.4    Nadas, A.5
  • 67
    • 0031769029 scopus 로고    scopus 로고
    • Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: Results of a retrospective nationwide seroprevalence survey
    • doi:10.1086/314498. PubMed: 9815232
    • Ludwig SL, Brundage JF, Kelley PW, Nang R, Towle C et al. (1998) Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey. J Infect Dis 178: 1776-1778. doi:10.1086/314498. PubMed: 9815232.
    • (1998) J Infect Dis , vol.178 , pp. 1776-1778
    • Ludwig, S.L.1    Brundage, J.F.2    Kelley, P.W.3    Nang, R.4    Towle, C.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.